The FPI work with a number of pharmaceutical companies on current and potential future clinical trials.
Current trials
- Alector AL001 Phase 2 trial for GRN mutation carriers – recruiting at a number of FPI centres [UCL, Erasmus, Toronto, London Ontario, Brescia, Ulm, Paris].
Companies with therapies for genetic FTD in development
- Ionis Pharmaceuticals in partnership with Biogen for MAPT and C9orf72 mutation carriers
- Prevail Therapeutics for GRN mutation carriers
- Wave Life Sciences for C9orf72 mutation carriers
- Arkuda for GRN mutation carriers
- Passage Bio for GRN mutation carriers
- Denali for GRN mutation carriers